BridgeBio Pharma (BBIO) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.78
- EPS estimate
- −$0.58
- EPS surprise
- −35.51%
- Revenue surprise
- +10.31%
- Revenue
- $243.7M
- Revenue estimate
- $220.9M
- Reported
- Aug 10, 2026
BridgeBio Pharma reported Q2 2026 results on August 10, 2026. It posted a loss of $0.78 per share, wider than the expected loss of $0.58, a miss of 35.51%. Revenue was $243.7 million, above the $220.9 million estimate and the highest in the table. Compared with Q2 2025, revenue rose about 120% from $110.6 million, and the loss per share narrowed from $0.95.
Every quarter in the table was a loss. The annual loss per share was $3.27 in 2022, $3.94 in 2023, $2.85 in 2024 and $3.78 in 2025. Revenue was small and uneven through 2024, mostly under $13 million a quarter, apart from $73.7 million in Q2 2022 and $211.1 million in Q1 2024. Since Q2 2025 it has risen every quarter, and annual revenue went from $221.9 million in 2024 to $502.1 million in 2025. BridgeBio beat the EPS estimate in six of the last 20 quarters and missed in each of the last four.
BridgeBio reported Q3 between October 29 and November 12 in each of the past five years. That points to late October to mid-November 2026. It will show whether revenue keeps climbing and how the loss compares.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 10, 2026 | −$0.58 | −$0.78 | −35.51% | $243.7M | SEC |
| Q1 2026 | May 7, 2026 | −$0.67 | −$0.84 | −25.49% | $194.5M | SEC |
| Q4 2025 | Feb 24, 2026 | −$0.71 | −$1.00 | −40.17% | $154.2M | SEC |
| Q3 2025 | Oct 29, 2025 | −$0.89 | −$0.95 | −6.25% | $120.7M | SEC |
| Q2 2025 | Aug 5, 2025 | −$0.79 | −$0.95 | −19.74% | $110.6M | SEC |
| Q1 2025 | Apr 29, 2025 | −$0.92 | −$0.88 | +4.13% | $116.6M | SEC |
| Q4 2024 | Feb 20, 2025 | −$1.12 | −$1.40 | −24.98% | $5.9M | SEC |
| Q3 2024 | Nov 12, 2024 | −$1.00 | −$0.86 | +14.28% | $2.7M | SEC |
| Q2 2024 | Aug 1, 2024 | −$1.00 | −$0.39 | +60.93% | $2.2M | SEC |
| Q1 2024 | May 2, 2024 | −$0.74 | −$0.20 | +72.86% | $211.1M | SEC |
| Q4 2023 | Feb 22, 2024 | −$0.87 | −$0.96 | −10.48% | $1.7M | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.79 | −$1.08 | −36.12% | $4.1M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.80 | −$0.98 | −22.68% | $1.6M | SEC |
| Q1 2023 | May 4, 2023 | −$0.82 | −$0.92 | −11.85% | $1.8M | SEC |
| Q4 2022 | Feb 23, 2023 | −$0.84 | −$0.92 | −9.77% | $1.9M | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.97 | −$0.93 | +3.94% | $338,000.00 | SEC |
| Q2 2022 | Aug 4, 2022 | −$0.56 | −$0.07 | +87.43% | $73.7M | SEC |
| Q1 2022 | May 5, 2022 | −$1.09 | −$1.35 | −24.28% | $1.7M | SEC |
| Q4 2021 | Feb 24, 2022 | −$0.88 | −$1.01 | −14.53% | $12.9M | SEC |
| Q3 2021 | Nov 4, 2021 | −$0.91 | −$1.06 | −15.90% | $2.3M | SEC |
Quarterly revenue
Frequently asked questions
When did BridgeBio Pharma (BBIO) last report earnings?
BridgeBio Pharma last reported on Aug 10, 2026, covering fiscal Q2 2026.
Did BBIO beat earnings estimates?
No. BridgeBio Pharma reported EPS of −$0.78 for Q2 2026 against a −$0.58 estimate — a 35.51% miss.
How much revenue did BBIO report last quarter?
BridgeBio Pharma reported $243.7M in revenue for Q2 2026, against a consensus estimate of $220.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.